

# **Pre/post-analytical surveys**


### a complementary service of EQA centers and valuable continuing education tool

Quality Control Centre Switzerland - Teamwork :

Xavier Albe Dagmar Kesseler Ð

Centre Suisse de Contrôle de Qualité Schweizerisches Zentrum für Qualitätskontrolle Centro Svizzero di Controllo della Qualitä Quality Control Centre Switzerland

### **Analysis cycle**



From Dr. Renze Bais, Royal North Shore Hospital, Sydney, with permission



## **Errors in laboratory testing**

- 68% pre-analytical phase
- 18% postanalytical phase
- Only 14% analytical phase

(Plebani & Carrano, Clin.Chem. 1997 : 43 : 1348-51)

 At present, fewer errors but the distribution in the different phases is roughly the same



# **Questionnaire setup**

- Multiple choice questionnaire (MCQ)
- 10 questions in 2 parts
  - Part I : general domains of laboratory analysis
  - Part II: specialised domains
- Evaluation on 5 or 10 questions
- Sample (1 survey)
- Twice a year
- Free of charge for CSCQ-members



## **Questionnaire validation**

### Preparation (CSCQ, FAMH student, ...)

(Foederatio Analyticorum Medicinalium Helveticorum - Ass.of Swiss Medical Laboratories)

# Control by CSCQ (scientific level, wording, ...) Validation by experts in the different specific fields



## **Results submission**

- Exclusively on the Web
- Simple clicks on checkboxes
- 3 languages available dynamically (French, Italian and German)



🖉 https://baal.hcuge.ch/cscq/EQAcom2/Apj	plic/Saisie.php?action=res&id=N1-5 - Windows Internet Explorer	
💽 🕞 👻 🙋 https://baal.hcuge.ch/cscq/EQAcor	n2/Applic/Saisie.php?action=res&id=N1-5	Softonic_France Customized Web Searl 🔎 🔻
Eichier Edition Affichage Fayoris Outils ?		
😭 🏟 🌈 https://baal.hcuge.ch/cscq/EQAcom2/A	pplic/Saisie.ph	🟠 👻 🔝 👘 🖶 🐑 Page 👻 🎯 O <u>u</u> tils 🚽
	EQACOM2 Quality Control Center Switzerland	Logged in on 2011-09-15 15:18:47
Survey         11-09-MB         11-09-MA         11-09-HE         11-09-HE         11-09-HE         11-09-HE         11-09-CH         → 11-06-PA         10-06-PA         Options         Modifications         Help: modification         Back	Results entry         Survey 11-06-PA of the laboratory 9997         Remember       Data entered on this page are taken into account by the CSCQ only if you click on bottom of this form), before changing pages (other survey or sample)         Warning ! Modification in the formulation of questions.         When the singular form is used in a question, one box only is to be ticked.         When the plural form is used in a question, several boxes are to be ticked.         When the plural form with the results you entered and stored into the CSCQ database)         Print (your form with the results you entered and stored into the CSCQ database)         1       Part of the questionnaire is based on general questions regarding pre- and post-analytical phases. Part II contains more questions. Would you like to be evaluated on part I only or on all questions?         1       Part I of the questions 2 to 6)         2       What is the INR used for?         1       Monitoring patients receiving oral anticoagulant therapy with vitamin K antagonists	the <u>Send to the CSCQ</u> button (at the



- (2 htt	ps (J/beal houge ch/cscu/EQAcom2/Applic/Solese php?actor=resbid=N1-%	🗶 🏭 👫 🕺 Suffranc, France Communit State Sea
ther Edition Alf	khaga Payon Quida 1	
· · ·	Baal Aruge. th/onty/EQActrix2(Apple/Same ph	💁 + 🔝 — 🎯 + 🕁 Baar + 🔂 O
Curren	11 OF DA of the leberatory 0007	
-	11-06-PA of the laboratory 9997	
Remember	Data entered on this page are taken into account by the bottom of this form), before changing pages (other sur	e CSCQ only if you click on the <u>Send to the CSCQ</u> button vey or sample)
When	the singular form is used in a quest the plural form is used in a question	n, several boxes are to be ticked.
Print (your	form with the results you entered and stored into the CSCQ da	(labase)
Print (your	form with the results you entered and stored into the CSCQ da	napase)
	form with the results you entered and stored into the CSCQ data	nabase)
Questionna Parti	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an	W255320
Questionna Parti	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions?	W255320
Questionna 1 Parti quest	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6)	W255370
Questionna 1 Part I guest	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11)	W255370
Questionna 1 Part I guest	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) tis the INR used for?	alytical phases. Part II contains more specific medical laboratory
Questionna 1 Part I guest	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) tis the INR used for? Monitoring patients receiving oral anticoagulant therapy with vitamin K an	alytical phases. Part II contains more specific medical laboratory
Questionna 1 Part I guest	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) tis the INR used for? Monitoring patients receiving oral anticoagulant therapy with vitamin K an Monitoring patients receiving standard heparin therapy	alytical phases. Part II contains more specific medical laboratory
Questionna 1 Part I guest	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) It is the INR used for? Monitoring patients receiving oral anticoagulant therapy with vitamin K an Monitoring patients receiving isomolecular weight heparin therapy	alytical phases. Part II contains more specific medical laboratory
Questionna 1 Parti quest 2 What 2 What 1	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) Part I (questions 2 to 6) and part II (questions 7 to 11) Tis the INR used for? Monitoring patients receiving oral anticoagulant therapy with vitamin K an Monitoring patients receiving standard heparin therapy Monitoring patients receiving low molecular weight heparin therapy Evaluating the coagulation intrinsic pathway factors	alytical phases. Part II contains more specific medical laboratory
Questionna 1 Parti quest 2 What 2 What 1	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on al questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) tist the INR used for? Monitoring patients receiving oral anticoagulant therapy with vitamin K an Monitoring patients receiving standard heparin therapy Monitoring patients receiving to molecular weight heparin therapy Evaluating the coagulation intrinsic pathway factors thereasons can explain a low hematocrit in an otherwise heatty patient?	alytical phases. Part II contains more specific medical laboratory
Questionna 1 Parti quest 2 What 2 What 1	aire on the pre and post-analytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on all questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) tis the INR used for? Monitoring patients receiving oral anticoagulant therapy with vitamin K an Monitoring patients receiving standard heparin therapy Monitoring patients receiving low molecular weight heparin therapy Evaluating the coagulation intrinsic pathway factors th reasons can explain a low hematocrit in an otherwise heathy patient? A significant time lapse between the blood collection and the analysis	alytical phases. Part II contains more specific medical laboratory
Questionna 1 Parti quest 2 What 2 What 1	aire on the pre and postanalytical phases of the questionnaire is based on general questions regarding pre- and post-an tions. Would you like to be evaluated on part I only or on al questions? Part I only (questions 2 to 6) Part I (questions 2 to 6) and part II (questions 7 to 11) tist the INR used for? Monitoring patients receiving oral anticoagulant therapy with vitamin K an Monitoring patients receiving standard heparin therapy Monitoring patients receiving to molecular weight heparin therapy Evaluating the coagulation intrinsic pathway factors thereasons can explain a low hematocrit in an otherwise heatty patient?	alytical phases. Part II contains more specific medical laboratory



36	· # https:	Ubaal.houge.ch/cscujEQAcom2/Applic/Solise.php?actor=resbid=NL=5	🗶 🔒 👫 🕺 Suffranc, Protein Communed with Search 🖉
Schier	Edition Affich	nga Fayona Quidis 1	
	8 Man //ba	al. houge. sh/songt QAcon2/Apple/Same.ph.c.	💁 • 🔯 🖷 👘 • 📄 Base • 🔘 Ogda •
En	quête	11-06-PA du laboratoire 9997	
Rap	pel		ses en compte par le CSCQ que si vous cliquez sur le bouton int de changer de page (autre enquête ou échantillon)
Q	uand	on ! Modification dans la formulat une question est écrite au singul une question est écrite au plurie	lier, un seul choix est à cocher.
_	10.000		
Imp	orimer (vot	re formulaire avec les résultats déjá saisis et mémorisés a	au CSCQ)
			IU CSCQ)
	stionnain La parté	re formulaire avec les résultats déjà saisis et mémorisés a e sur les phases pré et post-analytique el porte sur des questions générales des phases pré- et post-analytique ues. Souhaitez-vous être évalués uniquement sur la partie l ou sur la tot	rs, la partie Il concerne des domaines de médecine de laboratoire plus
	stionnain La parté	e sur les phases pré et post-analytique I porte sur des questions générales des phases pré- et post-analytique	rs, la partie Il concerne des domaines de médecine de laboratoire plus
	stionnain La parté	e sur les phases pré et post-analytique I porte sur des questions générales des phases pré- et post-analytique ues. Souhaitez-vous être évalués uniquement sur la partie I ou sur la tot	rs, la partie Il concerne des domaines de médecine de laboratoire plus
	stionnain La partie spécifiq	e sur les phases pré et post-analytique Tporte sur des questions générales des phases pré- et post-analytique ues. Souhaitez-vous être évalués uniquement sur la partie I ou sur la tot la partie I uniquement (questions 2 à 6)	rs, la partie Il concerne des domaines de médecine de laboratoire plus
	stionnain La partie spécifiq	e sur les phases pré et post-analytique I porte sur des questions générales des phases pré- et post-analytique ues. Souhaitez-vous être évalués uniquement sur la partie I ou sur la tot la partie I uniquement (questions 2 à 6) la partie I (questions 2 à 6) et la partie II (questions 7 à 11)	is, la partie Il concerne des domaines de médecine de laboratoire plus alité des questions ?
	stionnain La parte spécifiqu Quelle e	e sur les phases pré et post-analytique I porte sur des questions générales des phases pré- et post-analytique les. Souhaitez-vous être évalués uniquement sur la partie l ou sur la tot la partie l uniquement (questions 2 à 6) la partie l (questions 2 à 6) et la partie II (questions 7 à 11) st l'utilisation de l'INR ?	is, la partie Il concerne des domaines de médecine de laboratoire plus alité des questions ?
	stionnain La parte spécifiqu Quelle e	e sur les phases pré et post-analytique I porte sur des questions générales des phases pré- et post-analytique ues. Souhaitez-vous être évalués uniquement sur la partie l'ou sur la tot la partie l'uniquement (questions 2 à 6) la partie l'(questions 2 à 6) et la partie ll (questions 7 à 11) st l'utilisation de l'INR ? Surveiller la traitement des patients sous anticoagulant oral avec antai	rs, la partie II concerne des domaines de médecine de laboratoire plus alité des questions ? gonistes de la vitamine K
	stionnain La parte spécifiqu Quelle e	e sur les phases pré et post-analytique T porte sur des questions générales des phases pré- et post-analytique ues. Souhaitez-vous être évalués uniquement sur la partie l'ou sur la tot la partie l'uniquement (questions 2 à 6) la partie l (questions 2 à 6) et la partie ll (questions 7 à 11) st l'utilisation de l'INR ? Surveiller le traitement des patients sous anticoagulant oral avec antai Surveiller le traitement des patients sous héparine standard	ponistes de la vitamine K
Que:	Stionnain La partie spécifiqi Quelle e	e sur les phases pré et post-analytique I porte sur des questions générales des phases pré- et post-analytique les. Souhaitez-vous être évalués uniquement sur la partie l'ou sur la tot la partie l'uniquement (questions 2 à 0) la partie l'(questions 2 à 6) et la partie ll (questions 7 à 11) st l'utilisation de l'INR ? Surveiller le traitement des patients sous anticoagulant orai avec antai Surveiller le traitement des patients sous héparine standard Surveiller le traitement des patients sous héparine à bas poids molécu	es, la partie II concerne des domaines de médecine de laboratoire plus alité des questions ? gonistes de la vitamine K
	Stionnain La partie spécifiqi Quelle e	e sur les phases pré et post-analytique I porte sur des questions générales des phases pré- et post-analytique ues. Souhatez-vous être évalués uniquement sur la partie l ou sur la tot la partie l uniquement (questions 2 à 6) la partie l (questions 2 à 6) et la partie ll (questions 7 à 11) st l'utilisation de l'INR ? Surveiller le traitement des patients sous anticoaguiant oral avec antai Surveiller le traitement des patients sous héparine standard Surveiller le traitement des patients sous héparine à bas poids molécu Évaluer l'activité des facteurs de la voie intrinsèque de la coagulation	es, la partie II concerne des domaines de médecine de laboratoire plus alité des questions ? gonistes de la vitamine K
Que:	Stionnain La partie spécifiqi Quelle e	E sur les phases pré et post-analytique     Toorte sur des questions générales des phases pré- et post-analytique     Souhaitez-vous être évalués uniquement sur la partie l'ou sur la tot     la partie l'uniquement (questions 2 à 6)     la partie l'(questions 2 à 6) et la partie ll (questions 7 à 11)     st l'utilisation de l'INR ?     Surveiller le traitement des patients sous anticoagulant oral avec antai     Surveiller le traitement des patients sous héparine standard     Surveiller le traitement des patients sous héparine à bas poids molécu     Évaluer l'activité des facteurs de la voie intrinsèque de la coagulation     peuvent être les raisons d'un résultat d'hématocrite abaissé chez un sup	es, la partie II concerne des domaines de médecine de laboratoire plus alité des questions ? gonistes de la vitamine K alaire



### **Results evaluation**

### $\rightarrow$ Weighted MCQ evaluation:

Question n° 4	Correct choice	Participant selection	Weight	Example
Choice 1	Valid	V	m₁ if match nm₁ if mismatch	m <sub>1</sub>
Choice 2	Valid		m <sub>2</sub> if match nm <sub>2</sub> if mismatch	nm <sub>2</sub>
Choice 3	Not valid		m <sub>3</sub> if match nm <sub>3</sub> if mismatch	m <sub>3</sub>
Choice 4	Not valid		m <sub>4</sub> if match nm <sub>4</sub> if mismatch	m <sub>4</sub>

Response to the question accepted : if sum of weights > threshold



### **Global performance**

Question	Weight	Participant response	Example
1	<b>W</b> <sub>1</sub>	Accepted	W1
2	W2	Not accepted	0
3	<b>W</b> 3	Accepted	W3
4	W4	Accepted	W4
5	<b>W</b> 5	Not accepted	0
6	W <sub>6</sub>	Accepted	W <sub>6</sub>
7	W <sub>7</sub>	Accepted	W <sub>7</sub>
8	W8	Accepted	W <sub>8</sub>
9	W <sub>9</sub>	Accepted	Wg
10	<b>W</b> <sub>10</sub>	Not accepted	0
Total	30		$W_1 + W_3 + W_4 + W_6 + W_7 + W_8 + W_9$

- Score = sum of the weights
- FAC, performance factor

Score	FAC	Score	FAC
0 - 5	5 : bad	16 - 20	2 : borderline
6 - 10	4 : poor	21 - 25	1 : very good
11 - 15	3 : insufficient	26 - 30	0 : excellent




### Report (1)




#### COMMENTS ON THE RESULTS

 Question 2 had already been submitted in 2008 with the same evaluation criteria. The percentage of correct answers remains high and stable at 85 % (84 % in 2008) which is the highest percentage of correct answers in this survey.





### Report (2)





## Report (3)

	Received results	Correction	Result					01	ata FDF Supe MS
vise ł	nealthy patient	1?		articipants 35%)	Received results	Correction	Result	Your lab Correct answer	
the	174 (38%)	$\otimes$		in an otherwise i	healthy patien				
		0	- 4	llection and the	174 (38%)	$\otimes$			
s	351 (78%)	$\otimes$		the analysis tube	351 (78%) 306 (68%)	88			
-	306 (68%)				267 (59%)	$\otimes$			
		$\otimes$		2 d 6	NOO			1	
	267 (59%)	$\otimes$	X						



## Report (4)

3	Edit View Docume		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	• 30	• ia							Consta PD	f from MS.Qffca gwhare
Pape		Question Weight: 3	10	t answers : 1	All participar 28/389 (33%)	nts Received results	c	Correction	Res	Your ult Wr	lab ong answ	er 🔴	0
		detection te	st in a throa	t swab?	y interfere with th or 48 hours prior	e result obtained w	100.0242	rapid beta h	aemoly	/tic Strepto	coccus A	2	
<b>•</b> • •			Α	I partici	pants	Received					Yo	our Ial	b
Question <b>7</b> Weight: 3	Correct	answers		39 (33%)	-	results	С	Correctio	on	Resu	t ۱	Wrong	g answe
	llowing sit	uations r	: 128/38	39 (33%)			-						•



### Report (5)


**Comments** Very few participants (11%) dared ticking the four boxes, although all were correct. We considered the answer as correct if at least 3 out of 4 boxes were ticked. Group A streptococcus bacteria are the major cause of bacterial pharyngitis. Using rapid antigen tests to detect group A beta-haemolytic streptococci allows faster diagnosis, but several pre-analytical situations may impact the result.

The swab must be quickly analysed, the manufacturer's instructions specify the maximum storage time. Using two swabs for each collection process is recommended in order to increase the inoculum size, especially with a low number of bacteria.

Swab contact with mucous membranes and teeth may interfere with the analysis. Among potential effects are abnormal sample migration, non specific fixation, or sample dilution.

Rapid kits have to be used at room temperature. Low kit temperature may affect the chemical reaction allowing the visualisation of results.

((Facklam R.R., and Washington II, J.A., Streptococcus and Related Catalase-Negative Gram-Positive Cocci. In: Manual of Clinical Microbiology, Balows A., ed. 5th Edition, 1991, 29: 241)





### **A complementary service**

- Analytical phase is widely investigated while representing only 1/7 of the errors
- Only a small number of pre-analytical errors can be revealed by "analytical phase" surveys (errors in storage, ...)
- Awareness of the importance of the pre and post analytical phases

17



# **Continuing education tool for each actor**


- FAMH-student
- Internal CSCQ staff formation
- Experts (benefits from participant feed-back)
- Medical office staff: often the only continuing education
- Professional laboratories

   → first meeting to select the choices
   → second meeting to discuss argued answers

Ð

Centre Suisse de Contrôle de Qualité Schweizerisches Zentrum für Qualitätskontrolle Centro Svizzero di Controllo della Qualitä Quality Control Centre Switzerland


### **Statistics (1)**



Ð

Centre Suisse de Contrôle de Qualité Schweizerisches Zentrum für Qualitätskontrolle Centro Svizzero di Controllo della Qualitä Quality Control Centre Switzerland

### **Statistics (2)**





# Conclusions

- Surveys available in 3 languages
- Two participation levels (5 / 10 questions)
- Easy tool for submission
- Extensive report
- High number of participants despite non mandatory
- Recognized by FAMH and Swiss Society of Clinical Chemistry as continuing education
- Belongs to the accredited domain



### Prospective

- Extension to schemes including laboratory data
- Open to English speaking people
- Exchange of questions with others EQA Centres